Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 57
Filter
Add more filters

Complementary Medicines
Country/Region as subject
Publication year range
1.
J Ethnopharmacol ; 326: 117929, 2024 May 23.
Article in English | MEDLINE | ID: mdl-38373661

ABSTRACT

ETHNOPHARMACOLOGICAL RELEVANCE: Ya-Samarn-Phlae (YaSP) has traditionally been widely used in southern Thailand for treating chronic and infected wounds, including diabetic foot ulcers. However, there are only a limited number of clinical studies supporting the use of this polyherbal formulation. Therefore, the present work aims to provide clinical evidence to support the application of YaSP, prepared according to a standardized traditional procedure (T-YaSP). Additionally, its potential chemical markers and wound healing-related biological activities were examined. MATERIALS AND METHODS: The in vitro wound healing-related biological activities of YaSP ethanol extract and T-YaSP, including antibacterial activity against Staphylococcus epidermidis, inhibition and eradication of staphylococcal biofilm, anti-inflammatory effects, and enhancement of human dermal fibroblast migration in scratch wounds, were examined using well-established protocols. The chemical profiles of the ethanol extract of YaSP and T-YaSP were compared, and with promising chemical markers, arecoline, alpha-mangostin, and curcumin were selected and quantified using the HPLC method. A prospective, multicenter, randomized, controlled, parallel-group study was conducted over 12 weeks to evaluate the efficacy of the YaSP solution as an adjunct therapy, combined with standard wound care, for diabetic ulcers compared to standard treatment. RESULTS: The YaSP extract reduces NO production and can scavenge NO radicals in LPS-induced RAW 264.7 macrophage cells. Additionally, in a scratch assay, this extract and one of its herbal components, Curcuma longa, enhance the migration of human dermal fibroblasts. T-YaSP, containing 2.412 ± 0.002 mg/g of arecoline, 2.399 ± 0.005 mg/g of curcumin, and 0.017 ± 0.000 mg/g of α-mangostin, has shown the ability to inhibit the development and eradicate the mature biofilm of S. epidermidis. The use of T-YaSP as an adjunct therapy led to a significantly higher proportion of patients achieving healing within six weeks compared to the standard treatment group (36%/9 patients vs. 4%/1 patient; p = 0.013). After 12 weeks, 19 out of 25 patients in the T-YaSP group experienced complete healing, whereas only four patients in the standard treatment group achieved complete wound healing (76% in the T-YaSP group vs. 16% in the control group; p < 0.001). CONCLUSION: The results presented here represent the first randomized controlled trial to demonstrate the effectiveness of the traditional polyherbal solution, T-YaSP, which exhibits a wide range of wound healing-related activities. Utilizing T-YaSP as an adjunctive treatment resulted in a significant improvement in the number of type 2 diabetic patients achieving complete healing. However, to explore and utilize YaSP further, conducting a double-blind, randomized controlled trial with a larger population is necessary.


Subject(s)
Curcumin , Diabetes Mellitus , Diabetic Foot , Humans , Arecoline/pharmacology , Prospective Studies , Curcumin/pharmacology , Wound Healing , Plant Extracts/pharmacology , Plant Extracts/therapeutic use , Diabetic Foot/drug therapy , Double-Blind Method , Ethanol/pharmacology
2.
Phytomedicine ; 123: 155157, 2024 Jan.
Article in English | MEDLINE | ID: mdl-37951147

ABSTRACT

BACKGROUND: Bacopa monnieri (BM) is traditionally used in human diseases for its antioxidant, anti-inflammatory and neuroprotective effects. However, its anticancer potential has been poorly understood. AIM: The aim of this study was to explore the detailed anticancer mechanism of BM against oral cancer and to identify the bioactive BM fraction for possible cancer therapeutics. RESULTS: We performed bioactivity-guided fractionation and identified that the aqueous fraction of the ethanolic extract of BM (BM-AF) had a potent anticancer potential in both in vitro and in vivo oral cancer models. BM-AF inhibited cell viability, colony formation, cell migration and induced apoptotic cell death in Cal33 and FaDu cells. BM-AF at low doses promoted mitophagy and BM-AF mediated mitophagy was PARKIN dependent. In addition, BM-AF inhibited arecoline induced reactive oxygen species production in Cal33 cells. Moreover, BM-AF supressed arecoline-induced NLR family pyrin domain containing 3 (NLRP3) inflammasome activation through mitophagy in Cal33 cells. The in vivo antitumor effect of BM-AF was further validated in C57BL/6J mice through a 4-nitroquinolin-1-oxide and arecoline-induced oral cancer model. The tumor incidence was significantly reduced in the BM-AF treated group. Further, data obtained from western blot and immunohistochemistry analysis showed increased expression of apoptotic markers and decreased expression of inflammasome markers in the tongue tissue obtained from BM-AF treated mice in comparison with the non-treated tumor bearing mice. CONCLUSION: In conclusion, BM-AF exhibited potent anticancer activity through apoptosis induction and mitophagy-dependent inhibition of NLRP3 inflammasome activation in both in vitro and in vivo oral cancer models. Moreover, we have investigated apoptosis and mitophagy-inducing compounds from this plant extract having anticancer activity against oral cancer cells.


Subject(s)
Bacopa , Carcinoma, Squamous Cell , Head and Neck Neoplasms , Mouth Neoplasms , Mice , Humans , Animals , Inflammasomes/metabolism , NLR Family, Pyrin Domain-Containing 3 Protein/metabolism , Mitophagy , Bacopa/metabolism , Carcinoma, Squamous Cell/drug therapy , Squamous Cell Carcinoma of Head and Neck , Arecoline/pharmacology , Mouth Neoplasms/drug therapy , Mice, Inbred C57BL , Apoptosis , Reactive Oxygen Species/metabolism
3.
Brain Res ; 1822: 148609, 2024 01 01.
Article in English | MEDLINE | ID: mdl-37783259

ABSTRACT

BACKGROUND: It is unclear whether acupuncture has a rapid antidepressant effect and what is the main mechanism. METHODS: In this study, forced swimming stress test (FST) in mice were divided into five groups: control group, acupuncture group, scopolamine group, arecoline group, and acupuncture + arecoline group. Chronic unpredictable mild stress (CUMS) model rats were divided into six groups: naïve (non-CUMS) group, CUMS group, acupuncture group, scopolamine group, arecoline group, and acupuncture + arecoline group. Twenty-four hours after the end of treatment, FST was conducted in mice and rats. The expression of M1-AchR, AMPA receptors (GluR1 and GluR2), BDNF, mTOR, p-mTOR, synapsin I, and PSD95 in the prefrontal cortex was determined by western blot. The spine density of neurons in the prefrontal cortex was detected by golgi staining. RESULTS: The results showed that acupuncture reduced the immobility time of FST in two depression models. Acupuncture inhibited the expression of M1-AchR and promoted the expression of GluR1, GluR2, BDNF, p-mTOR, synapsin I, PSD95, and increased the density of neuron dendritic spine in the prefrontal cortex. CONCLUSIONS: The rapid antidepressant effect of acupuncture may be activating the "glutamate tide" - AMPA receptor activation - BDNF release - mTORC1 pathway activation through inhibiting the expression of M1-AchR in the prefrontal cortex, thereby increasing the expression of synaptic proteins and regulating synaptic plasticity.


Subject(s)
Acupuncture Therapy , Depression , Rats , Mice , Animals , Depression/therapy , Depression/metabolism , Brain-Derived Neurotrophic Factor/metabolism , Synapsins/metabolism , Arecoline/metabolism , Arecoline/pharmacology , Antidepressive Agents/pharmacology , Antidepressive Agents/metabolism , TOR Serine-Threonine Kinases/metabolism , Disease Models, Animal , Scopolamine/pharmacology , Prefrontal Cortex/metabolism , Neuronal Plasticity , Hippocampus/metabolism , Stress, Psychological/therapy , Stress, Psychological/metabolism
4.
Int J Mol Sci ; 24(10)2023 May 19.
Article in English | MEDLINE | ID: mdl-37240342

ABSTRACT

Areca nut (AN) is used for traditional herbal medicine and social activities in several countries. It was used as early as about A.D. 25-220 as a remedy. Traditionally, AN was applied for several medicinal functions. However, it was also reported to have toxicological effects. In this review article, we updated recent trends of research in addition to acquire new knowledge about AN. First, the history of AN usage from ancient years was described. Then, the chemical components of AN and their biological functions was compared; arecoline is an especially important compound in AN. AN extract has different effects caused by different components. Thus, the dual effects of AN with pharmacological and toxicological effects were summarized. Finally, we described perspectives, trends and challenges of AN. It will provide the insight of removing or modifying the toxic compounds of AN extractions for enhancing their pharmacological activity to treat several diseases in future applications.


Subject(s)
Plant Extracts , Plants, Medicinal , Plant Extracts/chemistry , Areca/adverse effects , Areca/chemistry , Nuts/chemistry , Arecoline/pharmacology
5.
Nutrients ; 15(10)2023 May 21.
Article in English | MEDLINE | ID: mdl-37242285

ABSTRACT

The areca nut is often consumed as a chewing food in the Asian region. Our previous study revealed that the areca nut is rich in polyphenols with high antioxidant activity. In this study, we further assessed the effects and molecular mechanisms of the areca nut and its major ingredients on a Western diet-induced mice dyslipidemia model. Male C57BL/6N mice were divided into five groups and fed with a normal diet (ND), Western diet (WD), WD with areca nut extracts (ANE), areca nut polyphenols (ANP), and arecoline (ARE) for 12 weeks. The results revealed that ANP significantly reduced WD-induced body weight, liver weight, epididymal fat, and liver total lipid. Serum biomarkers showed that ANP ameliorated WD-enhanced total cholesterol and non-high-density lipoprotein (non-HDL). Moreover, analysis of cellular signaling pathways revealed that sterol regulatory element-binding protein 2 (SREBP2) and enzyme 3-hydroxy-3-methylglutaryld coenzyme A reductase (HMGCR) were significantly downregulated by ANP. The results of gut microbiota analysis revealed that ANP increased the abundance of beneficial bacterium Akkermansias and decreased the abundance of the pathogenic bacterium Ruminococcus while ARE shown the opposite result to ANP. In summary, our data indicated that areca nut polyphenol ameliorated WD-induced dyslipidemia by increasing the abundance of beneficial bacteria in the gut microbiota and reducing the expressions of SREBP2 and HMGCR while areca nut ARE inhibited this improvement potential.


Subject(s)
Areca , Non-alcoholic Fatty Liver Disease , Male , Mice , Animals , Areca/chemistry , Non-alcoholic Fatty Liver Disease/drug therapy , Non-alcoholic Fatty Liver Disease/etiology , Nuts , Diet, Western/adverse effects , Mice, Inbred C57BL , Arecoline/pharmacology , Plant Extracts/pharmacology
6.
Phytomedicine ; 69: 153195, 2020 Apr.
Article in English | MEDLINE | ID: mdl-32200293

ABSTRACT

BACKGROUND: Areca nut has anti-inflammatory, antiparasitic, antihypertensive, and antidepressant properties. The pathological hallmarks of inflammatory joint diseases are an increased number of osteoclasts and impaired differentiation of osteoblasts, which may disrupt the bone remodeling balance and eventually lead to bone loss. PURPOSE: The present study assessed the effects of arecoline, the main alkaloid found in areca nut, on osteoclast and osteoblast differentiation and function. METHOD: M-CSF/RANKL-stimulated murine bone marrow-derived macrophages (BMMs) were incubated with several concentrations of arecoline, and TRAP staining and pit formation were assessed to monitor osteoclast formation. Quantitative real-time RT-PCR and western blot analyses were used to analyze the expression of osteoclast-associated genes and signaling pathways. The effects of arecoline on bone were investigated in an in vivo mouse model of lipopolysaccharide (LPS)-induced trabecular bone loss after oral administration of arecoline. Alizarin red S staining and assays to measure ALP activity and the transcription level of osteoblast-related genes were used to evaluate the effects of arecoline on osteoblast differentiation and bone mineralization. RESULTS: In a dose-dependent manner, arecoline at concentrations of 50-100 µM reduced both the development of TRAP-positive multinucleated osteoclasts and the formation of resorption pits in M-CSF/RANKL-stimulated BMMs. In M-CSF/RANKL-stimulated BMMs, arecoline also suppressed the expression and translocation of c-Fos and NFATcl, and osteoclast differentiated-related genes via interference with the AKT, MAPK, and NF-kB activation pathways. Femur bone loss and microcomputed tomography parameters were recovered by oral administration of arecoline in the mouse LPS-induced bone loss model. Lastly, arecoline increased ALP activity, bone mineralization, and the expression of osteoblast differentiation-related genes, such as ALP and Runx2, in MC3T3-E1 cells. CONCLUSION: Our data suggest that arecoline may attenuate or prevent bone loss by suppressing osteoclastogenesis and promoting osteoblastogenesis. These findings provide evidence supporting arecoline's use as a potential therapeutic agent in bone-loss disorders and diseases.


Subject(s)
Arecoline/pharmacology , Bone Resorption/drug therapy , Osteoclasts/drug effects , Animals , Bone Resorption/metabolism , Bone Resorption/pathology , Cell Differentiation/drug effects , Cells, Cultured , Gene Expression Regulation/drug effects , Genes, fos , Lipopolysaccharides/toxicity , Macrophages/drug effects , Male , Mice, Inbred DBA , NFATC Transcription Factors/genetics , NFATC Transcription Factors/metabolism , Osteoblasts/drug effects , Osteoblasts/physiology , Osteoclasts/cytology , Osteoclasts/physiology , Osteogenesis/drug effects , Osteoporosis/chemically induced , Osteoporosis/drug therapy , RANK Ligand/metabolism , RANK Ligand/pharmacology , X-Ray Microtomography
7.
Aging (Albany NY) ; 11(23): 11624-11639, 2019 12 12.
Article in English | MEDLINE | ID: mdl-31831717

ABSTRACT

BACKGROUND: There are 200-600 million betel quid (BQ) chewers in the world. BQ increases oral cancer risk. Matrix metalloproteinase-9 (MMP-9) is responsible for matrix degradation, cancer invasion and metastasis. Whether areca nut extract (ANE), a BQ component, stimulates MMP-9 secretion, and the related signaling pathways awaits investigation. RESULTS: ANE (but not arecoline) stimulated MMP-9 production of gingival keratinocytes and SAS cancer epithelial cells. ANE stimulated TGF-ß1, p-Smad2, and p-TAK1 protein expression. ANE-induced MMP-9 production/expression in SAS cells can be attenuated by SB431542 (ALK5/Smad2 inhibitor), 5Z-7-Oxozeaenol (TAK1 inhibitor), catalase, PD153035 (EGFR tyrosine kinase inhibitor), AG490 (JAK inhibitor), U0126 (MEK/ERK inhibitor), LY294002 (PI3K/Akt inhibitor), betel leaf (PBL) extract, and hydroxychavicol (HC, a PBL component), and melatonin, but not by aspirin. CONCLUSIONS: AN components contribute to oral carcinogenesis by stimulating MMP-9 secretion, thus enhancing tumor invasion/metastasis. These events are related to reactive oxygen species, TGF-ß1, Smad2-dependent and -independent signaling, but not COX. These signaling molecules can be biomarkers of BQ carcinogenesis. PBL, HC and melatonin and other targeting therapy can be used for oral cancer treatment. METHODS: ANE-induced MMP-9 expression/secretion of oral epithelial cells and related TGF-ß1, Smad-dependent and -independent signaling were studied by MTT assay, RT-PCR, western blotting, immunofluorescent staining, and ELISA.


Subject(s)
Areca , Epithelial Cells/drug effects , Matrix Metalloproteinase 9/metabolism , Plant Extracts/pharmacology , Smad2 Protein/metabolism , Transforming Growth Factor beta/metabolism , Arecoline/pharmacology , Cell Line, Tumor , Cell Survival/drug effects , Epithelial Cells/metabolism , Eugenol/analogs & derivatives , Eugenol/pharmacology , Gene Expression Regulation/drug effects , Humans , Matrix Metalloproteinase 9/genetics , Melatonin/pharmacology , Plant Extracts/chemistry , Plant Leaves/chemistry , Smad2 Protein/genetics , Transforming Growth Factor beta/genetics
8.
J Formos Med Assoc ; 117(6): 527-534, 2018 Jun.
Article in English | MEDLINE | ID: mdl-28720506

ABSTRACT

BACKGROUND/PURPOSE: Oral submucous fibrosis (OSF) is a premalignant condition caused by the chewing of areca nut (AN). Transforming growth factor ß (TGFß) plays a central role in the pathogenesis of OSF. Connective tissue growth factor (CTGF or CCN2) and early growth response-1 (Egr-1) are important mediators in the fibrotic response to TGFß in several fibrotic disorders including OSF. Arecoline, a major AN alkaloid, induced the synthesis of CCN2 and Egr-1 in human buccal mucosal fibroblast (BMFs). The aims of this study were to investigate whether arecoline-induced CCN2 and Egr-1 syntheses are mediated through TGFß1 signaling and to inspect the detailed mechanisms involved. METHODS: Western blot and TGFß1 Emax® ImmunoAssay were used to measure the effect of arecoline on the TGFß signaling pathways. 2',7'-dichlorodihydrofluorescein diacetate and MitoSOX™ Red were used to measure the effect of arecoline on the cellular and mitochondrial reactive oxygen species (ROS). RESULTS: Arecoline induced latent TGFß1 activation, Smad2 phosphorylation, and mitochondrial and total cellular ROS in BMFs. TGFß-neutralizing antibody completely inhibited the arecoline-induced synthesis of CCN2 and Egr-1. Mito-TEMPO, a mitochondria-targeted antioxidant, completely suppressed arecoline-induced latent TGFß1 activation and mitochondrial and total cellular ROS. Epigallocatechin-3-gallate (EGCG) dose-dependently inhibited arecoline-induced TGFß1 activation and mitochondrial ROS in BMFs. CONCLUSION: Our results indicated that arecoline-induced mitochondrial ROS plays pivotal roles in the activation of latent TGFß1 leading to the initiation of TGFß1 signaling and subsequent increase in the synthesis of CCN2 and Egr-1. EGCG can be a useful agent in the chemoprevention and treatment of OSF.


Subject(s)
Areca/adverse effects , Arecoline/pharmacology , Catechin/analogs & derivatives , Smad2 Protein/metabolism , Transforming Growth Factor beta1/metabolism , Blotting, Western , Catechin/pharmacology , Cells, Cultured , Connective Tissue Growth Factor/metabolism , Early Growth Response Protein 1/genetics , Early Growth Response Protein 1/metabolism , Fibroblasts/drug effects , Fibroblasts/metabolism , Humans , Immunoassay , Mitochondria/metabolism , Mouth Mucosa/pathology , Oral Submucous Fibrosis/chemically induced , Phosphorylation/drug effects , Plant Extracts/pharmacology , Plants, Toxic/adverse effects , Reactive Oxygen Species/metabolism , Signal Transduction/drug effects , Smad2 Protein/genetics , Transforming Growth Factor beta1/genetics
9.
Am J Chin Med ; 41(4): 865-85, 2013.
Article in English | MEDLINE | ID: mdl-23895157

ABSTRACT

The present study provides in vitro and in vivo evaluation of arecoline on peripheral nerve regeneration. In the in vitro study, we found that arecoline at 50 µg/ml could significantly promote the survival and outgrowth of cultured Schwann cells as compared to the controls treated with culture medium only. In the in vivo study, we evaluated peripheral nerve regeneration across a 10-mm gap in the sciatic nerve of the rat, using a silicone rubber nerve chamber filled with the arecoline solution. In the control group, the chambers were filled with normal saline only. At the end of the fourth week, morphometric data revealed that the arecoline-treated group at 5 µg/ml significantly increased the number and the density of myelinated axons as compared to the controls. Immunohistochemical staining in the arecoline-treated animals at 5 µg/ml also showed their neural cells in the L4 and L5 dorsal root ganglia ipsilateral to the injury were strongly retrograde-labeled with fluorogold and lamina I-II regions in the dorsal horn ipsilateral to the injury were significantly calcitonin gene-related peptide-immunolabeled compared with the controls. In addition, we found that the number of macrophages recruited in the distal sciatic nerve was increased as the concentration of arecoline was increased. Electrophysiological measurements showed the arecoline-treated groups at 5 and 50 µg/ml had a relatively larger nerve conductive velocity of the evoked muscle action potentials compared to the controls. These results indicate that arecoline could stimulate local inflammatory conditions, improving the recovery of a severe peripheral nerve injury.


Subject(s)
Arecoline/pharmacology , Cholinergic Agonists/pharmacology , Nerve Regeneration/drug effects , Peripheral Nerve Injuries , Sciatic Nerve/drug effects , Action Potentials/drug effects , Animals , Apoptosis/drug effects , Calcitonin Gene-Related Peptide/drug effects , Calcitonin Gene-Related Peptide/metabolism , Caspase 3/drug effects , Caspase 3/metabolism , Caspase 9/drug effects , Caspase 9/metabolism , Cell Survival/drug effects , Cells, Cultured , Cytochromes c/drug effects , Cytochromes c/metabolism , Nerve Growth Factor/drug effects , Nerve Growth Factor/genetics , Nerve Growth Factor/metabolism , Neural Conduction/drug effects , Rats , Rats, Sprague-Dawley , Schwann Cells/drug effects , Sciatic Nerve/metabolism , bcl-2-Associated X Protein/drug effects , bcl-2-Associated X Protein/metabolism
10.
PLoS One ; 8(7): e67985, 2013.
Article in English | MEDLINE | ID: mdl-23874481

ABSTRACT

BACKGROUND: Snail is an important transcription factor implicated in several tumor progression and can be induced by reactive oxygen species (ROS). Areca quid chewing is a major risk factor of oral squamous cell carcinoma (OSCC). Therefore, we hypothesize that the major areca nut alkaloid arecoline may induce Snail via ROS and involve in the pathogenesis of areca quid chewing-associated OSCC. METHODOLOGY/PRINCIPAL FINDING: Thirty-six OSCC and ten normal oral epithelium specimens were examined by immunohistochemistry and analyzed by the clinico-pathological profiles. Cytotoxicity, 2', 7'-dichlorofluorescein diacetate assay, and western blot were used to investigate the effects of arecoline in human oral keratinocytes (HOKs) and oral epithelial cell line OECM-1 cells. In addition, antioxidants N-acetyl-L-cysteine (NAC), curcumin, and epigallocatechin-3 gallate (EGCG) were added to find the possible regulatory mechanisms. Initially, Snail expression was significantly higher in OSCC specimens (p<0.05). Elevated Snail expression was associated with lymph node metastasis (p = 0.031) and poor differentiation (p = 0.017). Arecoline enhanced the generation of intracellular ROS at the concentration higher than 40 µg/ml (p<0.05). Arecoline was also found to induced Snail expression in a dose- and time-dependent manner (p<0.05). Treatment with NAC, curcumin, and EGCG markedly inhibited arecoline induced Snail expression (p<0.05). CONCLUSION/SIGNIFICANCE: Our results suggest that Snail overexpression in areca quid chewing-associated OSCC is associated with tumors differentiation and lymph node metastasis. Arecoline-upregulated Snail expression may be mediated by ROS generation. In addition, arecoline induced Snail expression was downregulated by NAC, curcumin, and EGCG.


Subject(s)
Areca/adverse effects , Carcinoma, Squamous Cell/chemically induced , Carcinoma, Squamous Cell/pathology , Mouth Neoplasms/chemically induced , Mouth Neoplasms/pathology , Plant Extracts/adverse effects , Transcription Factors/genetics , Adult , Aged , Aged, 80 and over , Arecoline/adverse effects , Arecoline/pharmacology , Cells, Cultured , Disease Progression , Female , Gene Expression Regulation, Neoplastic/drug effects , Humans , Lymphatic Metastasis , Male , Mastication/physiology , Middle Aged , Reactive Oxygen Species/adverse effects , Snail Family Transcription Factors , Up-Regulation/drug effects
11.
Acta Pharmacol Sin ; 33(8): 1023-9, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22820911

ABSTRACT

AIM: To investigate the effect of arecoline, a major component of betel nut, on vascular endothelial function in high fructose-fed rats and the potential mechanisms underlying the effect. METHODS: Male Wistar rats were fed a high-fructose or control diet for 16 weeks. At the beginning of week 13, the rats were injected ip with low (0.5 mg·kg(-1)·d(-1)), medium (1.0 mg·kg(-1)·d(-1)) or high (5.0 mg·kg(-1)·d(-1)) doses of arecoline for 4 weeks. At the termination of the treatments, blood was collected, fasting blood glucose (FBG) and serum insulin (FSI) levels were measured, and insulin sensitivity index (ISI) was calculated. The thoracic aortas were isolated and aortic rings were prepared for studying ACh-induced endothelium-dependent vasorelaxation (EDVR). The mRNA and protein expression of cystathionine-γ-lyase (CSE) in the thoracic aortas was analyzed using RT-PCR and Western blot analysis, respectively. RESULTS: In high fructose-fed rats, the levels of FBG and FSI were remarkably increased, whereas the ISI and the mRNA and protein expression of CSE were significantly decreased. ACh-induced EDVR in the aortic rings from high fructose-fed rats was remarkably reduced. These changes were reversed by treatment with high dose arecoline. Pretreatment of the aortic rings rings from high fructose-fed rats with the CSE inhibitor propargylglycine (10 mmol/L) or the ATP-sensitive potassium (K(ATP)) channel blocker glibenclamide (10 mmol/L) abolished the restoration of ACh-induced EDVR by high dose arecoline. On the contrary, treatment with high dose arecoline significantly impaired ACh-induced EDVR in the aortic rings from control rats, and pretreatment with propargylglycine or glibenclamide did not cause further changes. CONCLUSION: Arecoline treatment improves ACh-induced EDVR in high fructose-fed rats, and the potential mechanism of action might be associated with increase of CSE expression and activation of K(ATP) channels by arecoline.


Subject(s)
Arecoline/pharmacology , Cystathionine gamma-Lyase/biosynthesis , Endothelium, Vascular/drug effects , Endothelium, Vascular/enzymology , Fructose/toxicity , KATP Channels/metabolism , Animals , Aorta, Thoracic/drug effects , Aorta, Thoracic/enzymology , Dose-Response Relationship, Drug , Endothelium, Vascular/physiology , Fructose/administration & dosage , Gene Expression Regulation, Enzymologic , Male , Organ Culture Techniques , Rats , Rats, Wistar
12.
PLoS One ; 7(12): e51806, 2012.
Article in English | MEDLINE | ID: mdl-23284772

ABSTRACT

Oral submucous fibrosis (OSF) is a chronic inflammatory disease characterized by the accumulation of excess collagen, and areca nut chewing has been proposed as an important etiological factor for disease manifestation. Activation of transforming growth factor-ß signaling has been postulated as the main causative event for increased collagen production in OSF. Oral epithelium plays important roles in OSF, and arecoline has been shown to induce TGF-ß in epithelial cells. In an attempt to understand the role of areca nut constituents in the manifestation of OSF, we studied the global gene expression profile in epithelial cells (HaCaT) following treatment with areca nut water extract or TGF-ß. Interestingly, 64% of the differentially regulated genes by areca nut water extract matches with the TGF-ß induced gene expression profile. Out of these, expression of 57% of genes was compromised in the presence of ALK5 (TßRI) inhibitor and 7% were independently induced by areca nut, highlighting the importance of TGF-ß in areca nut actions. Areca nut water extract treatment induced p-SMAD2 and TGF-ß downstream targets in HaCaT cells but not in human gingival fibroblast cells (hGF), suggesting epithelial cells could be the source of TGF-ß in promoting OSF. Water extract of areca nut consists of polyphenols and alkaloids. Both polyphenol and alkaloid fractions of areca nut were able to induce TGF-ß signaling and its downstream targets. Also, SMAD-2 was phosphorylated following treatment of HaCaT cells by Catechin, Tannin and alkaloids namely Arecoline, Arecaidine and Guvacine. Moreover, both polyphenols and alkaloids induced TGF-ß2 and THBS1 (activator of latent TGF-ß) in HaCaT cells suggesting areca nut mediated activation of p-SMAD2 involves up-regulation and activation of TGF-ß. These data suggest a major causative role for TGF-ß that is induced by areca nut in OSF progression.


Subject(s)
Areca/adverse effects , Arecoline/analogs & derivatives , Biomarkers/metabolism , Nuts/adverse effects , Oral Submucous Fibrosis/etiology , Smad2 Protein/metabolism , Transforming Growth Factor beta/metabolism , Arecoline/pharmacology , Cells, Cultured , Collagen/metabolism , Fibroblasts/cytology , Fibroblasts/drug effects , Fibroblasts/metabolism , Gene Expression Profiling , Gingiva/cytology , Gingiva/drug effects , Gingiva/metabolism , Humans , Keratinocytes/cytology , Keratinocytes/drug effects , Keratinocytes/metabolism , Mastication , Oligonucleotide Array Sequence Analysis , Phosphorylation/drug effects , Plant Extracts/pharmacology , Plants, Toxic/adverse effects , RNA, Messenger/genetics , Real-Time Polymerase Chain Reaction , Reverse Transcriptase Polymerase Chain Reaction , Smad2 Protein/genetics , Transforming Growth Factor beta/genetics , Up-Regulation
13.
J Oral Pathol Med ; 40(10): 769-77, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21481006

ABSTRACT

BACKGROUND: Areca quid chewing is an etiological factor contributing to the development of oral cancer and pre-cancers, whose pathophysiology has been linked to inflammation and immune deterioration. Myeloid-derived suppressor cells (MDSC) play a key role in the regulation of immunity under certain pathological conditions, such as inflammation and cancer. As areca nut extracts (ANE) have been reported to induce a proinflammatory effect in antigen-stimulated mice, we hypothesized that ANE might enhance the development of MDSC. METHODS: Ovalbumin (OVA)-sensitized BALB/c mice were daily administered with ANE (5-50 mg/kg), polyphenol-enriched ANE (PANE; 25 mg/kg) or arecoline (5 mg/kg) by intraperitoneal injection for 10 doses. The mouse footpads were then subcutaneously challenged with OVA to induce local inflammatory responses. RESULTS: ANE and PANE treatment significantly increased the spleen index and the population of CD11b(+) Gr-1(+) cells in the spleen and peripheral blood, whereas arecoline was inactive. In addition, ANE and PANE treatment enhanced the expression of cytokines and enzymes associated with the immunosuppressive function of MDSC, including IL-10, arginase-I and iNOS in splenic CD11b(+) cells. Concordantly, ANE and PANE treatment augmented the infiltration of Gr-1(+) IL-10(+) cells in the footpads challenged with OVA. CONCLUSIONS: Our results suggested that areca nut constituents, in particular, polyphenols enhanced the development of myeloid-derived suppressor cells in vivo, which may be a critical mechanism linking inflammation and the compromised immunity reported to be associated with the pathophysiology of areca-related oral diseases.


Subject(s)
Areca , CD11b Antigen/drug effects , Immune Tolerance/immunology , Leukocytes, Mononuclear/drug effects , Myeloid Cells/drug effects , Nuts , Plant Extracts/pharmacology , Receptors, Chemokine/drug effects , Animals , Arecoline/pharmacology , Arginase/analysis , Body Weight , CD11b Antigen/immunology , Cell Culture Techniques , Chemotaxis, Leukocyte/immunology , Cholinergic Agonists/pharmacology , Immunization , Inflammation Mediators/immunology , Interleukin-10/analysis , Leukocytes, Mononuclear/immunology , Male , Mice , Mice, Inbred BALB C , Monocytes/drug effects , Monocytes/immunology , Myeloid Cells/immunology , Nitric Oxide Synthase Type II/analysis , Organ Size , Ovalbumin/immunology , Polyphenols/pharmacology , Receptors, Chemokine/immunology , Spleen/drug effects , Spleen/pathology
14.
Oral Oncol ; 47(4): 256-61, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21317023

ABSTRACT

Cyr61 is associated with growth and progression of many types of tumors and is an independent poor prognostic indicator for oral cancer patients. Areca nut (AN) chewing is the most important etiological factor in the pathogenesis of oral cancer in India and many Southeast Asian countries. Yet, the molecular mechanisms involved in the AN-induced oral cancer remain largely unknown. In this study, we show that arecoline, a main alkaloid found in AN, stimulated Cyr61 synthesis in human gingival epithelial S-G cells. Constitutive overexpression of Cyr61 protein in oral epithelial cells during AN chewing may play a role in the pathogenesis of oral cancer. ERK inhibitor PD98059, N-acetyl-L-cysteine, Rho-associated protein kinase (ROCK) selective inhibitor Y-27632 and a geranylgeranyltransferase inhibitor reduced the arecoline-stimulated levels of Cyr61 protein by ∼31%, 47%, 65% and 100%, respectively. Lovastatin also completely inhibited arecoline-induced Cyr61 synthesis and the inhibition is dose-dependent. Decreased of geranylgeranylated proteins could be the mechanism that lovastatin regulates Cyr61 synthesis and lovastatin could serve as a useful agent in controlling AN-induced oral cancer.


Subject(s)
Arecoline/pharmacology , Carcinoma, Squamous Cell/chemically induced , Cysteine-Rich Protein 61/metabolism , Gingiva/drug effects , Lovastatin/therapeutic use , Mouth Neoplasms/chemically induced , Plant Extracts/pharmacology , Areca/adverse effects , Areca/chemistry , Arecoline/antagonists & inhibitors , Blotting, Western , Carcinoma, Squamous Cell/metabolism , Cell Line, Tumor , Epithelial Cells/drug effects , Epithelial Cells/metabolism , Epithelial Cells/pathology , Gene Expression Regulation, Neoplastic , Gingiva/metabolism , Gingiva/pathology , Humans , Male , Mouth Neoplasms/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Up-Regulation
15.
Phytomedicine ; 18(4): 285-91, 2011 Feb 15.
Article in English | MEDLINE | ID: mdl-20724125

ABSTRACT

The present study analyses the effect of eugenol, arecoline and vanillic acid alone and in combination with two oral hypoglycemic drugs (OHD), namely, metformin and 2,4-thiazolodinedione (THZ), on 2-deoxyglucose (2DG) uptake in L6 myotubes. 2DG uptake in L6 myotubes was determined using an enzymatic assay developed by Yamamoto et al. (2006). Lipid content inside the cells has been estimated with oil red O assay. The absorption, distribution, metabolism, and excretion (ADME) and drug likeness properties of these phytochemicals are estimated using software QikProp(®). All the three phytochemicals enhance 2DG uptake both in time- and dose-dependent manner. Eugenol and arecoline enhances 2DG uptake synergistically with both the OHD; whereas vanillic acid showing partly synergy with THZ and antagonistic activity with metformin on 2DG uptake. Eugenol and arecoline significantly increase the expressions of the glucose transporter type 4 (GLUT4) and phosphoinositide 3-kinase (PI3K) genes, but not the peroxisome proliferator-activated receptor (PPAR) gamma. Whereas vanillic acid does not has any significant effect on the expressions of these genes, the ADME results indicate that these phytochemicals are satisfying all the conditions to have a good oral bioavailability. These findings suggest that these phytochemicals can replace the commercial drugs in part, which could lead to a reduction in toxicity and side effects caused by the later as well as reduce the secondary complications.


Subject(s)
Arecoline/pharmacology , Eugenol/pharmacology , Glucose/metabolism , Hypoglycemic Agents/pharmacology , Muscle Fibers, Skeletal/metabolism , Vanillic Acid/pharmacology , Administration, Oral , Animals , Biological Transport/drug effects , Deoxyglucose/analysis , Deoxyglucose/metabolism , Dose-Response Relationship, Drug , Drug Synergism , Drug Therapy, Combination , Hypoglycemic Agents/metabolism , Metformin/pharmacology , Muscle Fibers, Skeletal/drug effects , Rats , Thiazolidinediones/pharmacology
16.
Addiction ; 105(7): 1303-10, 2010 Jul.
Article in English | MEDLINE | ID: mdl-20642513

ABSTRACT

AIMS: Previously reported research suggests a dependence syndrome for areca nut use, though well-designed studies are virtually non-existent. The goal of this study was to examine evidence of areca dependence in a sample of areca-only (i.e. no tobacco) chewers using modified measurement scales. DESIGN: A purposive sample of chewers, identified via local informants and advertisements, was surveyed from January to March of 2005. SETTING: Six villages in Dakshina Kannada District, Karnataka State, India. PARTICIPANTS: Fifty-nine daily areca chewers who do not also currently use any form of tobacco. MEASUREMENTS: Questionnaires included modified versions of the Fagerström Tolerance Questionnaire, Cigarette Dependence Scale (CDS-5) and the Smokeless Tobacco Dependence Scale (STDS). Additional questions assessed demographic characteristics and patterns of use. FINDINGS: Approximately half of respondents reported 1-3 chews/day (mean = 1.9; SD = 0.98). The average number of chewing episodes/day was 4.4 (SD = 3.4) and the average number of nuts/day was 1.2 (SD = 1.1). Users' typical chew lasts up to 20 minutes and includes spitting out the juices and rinsing the mouth with water. Overall, the levels of reported dependence symptoms were quite low, but approximately 44% of chewers endorsed at least one of the following items: continued use despite illness or mouth wounds, difficulty refraining from chewing in forbidden places, or craving during periods of abstinence. Approximately 15.4% of chewers reported at least one intentional quit attempt and a subset had summary scores indicative of dependence (13.6% had scores >16 on the CDS-5 and 5.3% had scores >11 on the STDS). Dependence scores were positively correlated with frequency of chews/day. CONCLUSIONS: The symptoms of dependence observed in a subset of areca-only chewers warrant further investigation. Next steps should include well-controlled laboratory evaluation of dependence features.


Subject(s)
Areca , Behavior, Addictive/epidemiology , Health Knowledge, Attitudes, Practice , Plants, Medicinal , Substance-Related Disorders/epidemiology , Adolescent , Adult , Aged , Arecoline/pharmacology , Behavior, Addictive/psychology , Child , Female , Health Surveys , Humans , India/epidemiology , Male , Middle Aged , Substance Withdrawal Syndrome/psychology , Substance-Related Disorders/psychology , Surveys and Questionnaires , Young Adult
17.
Can J Physiol Pharmacol ; 88(4): 439-47, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20555412

ABSTRACT

Areca is a Chinese herbal medicine that is widely used for constipation. However the mechanisms of its action are not clear. We investigated the effects of arecoline, the most active component of areca, on the motility of rat distal colonic smooth muscle strips. In longitudinal muscle of distal colon (LMDC) and circular muscle of distal colon (CMDC), arecoline increased the contraction in a dose-dependent manner. Tetrodotoxin (TTX) did not inhibit the effects of arecoline. The contractile response to arecoline was completely antagonized by atropine. 4-Diphenylacetoxy-N-methylpiperidine methiodide (4-DAMP) strongly depressed the response to arecoline, but gallamine and methoctramine did not. Nifedipine, 2-aminoethoxydiphenyl borate (2-APB), and Ca2+-free Krebs solution with EGTA partly inhibited the effects of arecoline. The sum of Ca2+-free Krebs solution, EGTA, and 2-APB completely inhibited the effects of arecoline. The results show that arecoline stimulates distal colonic contraction in rats via the muscarinic (M3) receptor - extracellular Ca2+ influx - Ca2+ store release pathway. It is likely that the action of areca in relieving constipation is due to its stimulation of muscle contraction.


Subject(s)
Arecoline/pharmacology , Calcium/metabolism , Colon/drug effects , Muscarinic Agonists/pharmacology , Muscle Contraction/drug effects , Muscle, Smooth, Vascular/drug effects , Receptor, Muscarinic M3/agonists , Animals , Cholinergic Agonists/pharmacology , Colon/metabolism , Colon/physiology , Constipation/drug therapy , Dose-Response Relationship, Drug , Drugs, Chinese Herbal/therapeutic use , Female , In Vitro Techniques , Ion Transport , Muscarinic Antagonists/pharmacology , Muscle, Smooth, Vascular/metabolism , Muscle, Smooth, Vascular/physiology , Rats , Rats, Inbred BB , Receptor, Muscarinic M3/antagonists & inhibitors , Receptor, Muscarinic M3/metabolism , Tetrodotoxin/pharmacology
18.
Autophagy ; 4(7): 967-8, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18758233

ABSTRACT

We recently identified an autophagy-inducing areca nut ingredient (AIAI) in the partially purified 30-100 kDa fraction of areca nut extract (ANE), designated as ANE 30-100K. Before disintegration, most ANE 30-100K-treated cells exhibit rounding morphology, cytoplasmic clearance, and nuclear shrinkage, distinct from arecoline- and cisplatin-induced cellular apoptosis. This unique death pattern is verified to be autophagy by LC3-I cleavage, acidic vesicles, and autophagic vacuoles. As analyzed by Molish's Test, Selinowaff's Test, and thin-layer chromatography, most of the ANE 30-100K constituents are carbohydrates, whereas the protein content of this fraction is less than 1% as assessed by protein assay reagent. The cytotoxicity of ANE 30-100K is further shown to be sensitive to cellulase and proteinase K digestion suggesting AIAI in ANE 30-100K to be a proteoglycan (or glycoprotein). Thus, although ANE contains apoptosis-inducing ingredients such as arecoline, it predominantly triggers autophagic cell death by this natural AIAI.


Subject(s)
Areca/chemistry , Arecoline/pharmacology , Autophagy/drug effects , Plant Extracts/pharmacology , Apoptosis , Cell Line, Tumor , Humans
19.
J Periodontal Res ; 42(1): 69-76, 2007 Feb.
Article in English | MEDLINE | ID: mdl-17214642

ABSTRACT

BACKGROUND AND OBJECTIVE: Polymorphonuclear leukocytes (PMN) represent the first line of host defense. Areca nut extract inhibits the bactericidal activity of, and the release of superoxide anion (O2- ) by, PMN. This study investigated the effects of areca nut extract on the intracellular production of reactive oxygen species (ROS) and on the extracellular release of lysosomal enzyme, myeloperoxidase (MPO), by PMN. The effects of arecoline, a principal component of areca nut, were also examined. MATERIAL AND METHODS: Human PMN were treated with various concentrations of areca nut extract or arecoline followed by treatment with Hanks' balanced salt solution, with or without cytochalasin B and fMet-Leu-Phe (CB/fMLP). The viability of PMN was determined using propidium iodide staining and flow cytometry. The presence of intracellular ROS was determined using 2',7'-dichlorofluorescin diacetate and fluorometry. MPO release was determined using a substrate assay. RESULTS: Areca nut extract (25 and 50 microg/ml) significantly decreased the viability of PMN. The intracellular levels of ROS and the extracellular release of MPO were induced in PMN by CB/fMLP. Exposure of PMN to areca nut extract (up to 25 microg/ml) or to arecoline (up to 2 mg/ml) did not directly affect the levels of ROS and MPO activity. However, under conditions that did not affect the viability of PMN, the ability of CB/fMLP to trigger production of intracellular ROS and release of MPO in human PMN was significantly suppressed by areca nut extract and arecoline. CONCLUSION: Areca nut impaired the activation of PMN by CB/fMLP that might decrease the effectiveness of PMN in the host defense. Alternatively, exposure of PMN to areca nut extract could decrease the capacity of PMN to damage tissues.


Subject(s)
Areca , Neutrophils/drug effects , Nuts , Peroxidase/antagonists & inhibitors , Plant Extracts/pharmacology , Reactive Oxygen Species/antagonists & inhibitors , Arecoline/pharmacology , Cell Survival/drug effects , Coloring Agents , Cytochalasin B/pharmacology , Flow Cytometry , Fluorometry , Humans , N-Formylmethionine Leucyl-Phenylalanine/pharmacology , Neutrophils/enzymology , Superoxides/antagonists & inhibitors
20.
J Perinat Med ; 33(5): 399-405, 2005.
Article in English | MEDLINE | ID: mdl-16238534

ABSTRACT

This study investigated the effects of arecoline, an active ingredient of the areca nut, on the tone of human umbilical arteries and veins and on the eNOS expression and cell proliferation of human umbilical vein endothelial cells (HUVECs). We found that arecoline relaxes the human umbilical artery and vein rings in a concentration-dependent manner; the higher the concentration of arecoline, the greater the relaxation of the rings. However, the relaxation decreases after the endothelium was removed or pretreated with L-NAME, a nitric oxide synthase inhibitor. Moreover, arecoline increases in a dose-dependent way the cGMP levels of human umbilical arteries and veins. In HUVECs, arecoline also increases the eNOS expression. Therefore, the relaxant effects of arecoline on the umbilical artery and vein rings were endothelium-dependent through the NO-cGMP systems. In addition, arecoline at higher doses (100-1000 microM) inhibits endothelial cell proliferation; the exposure toarecoline (100-1000 microM) for 24 and 48 h induces G2/M cell cycle arrest of HUVECs. Our results indicate that arecoline would decrease vascular tone, in part mediated by NO. Higher doses of arecoline inhibit endothelial cell growth, which suggest that long-term use or high doses of areca nut might induce endothelial dysfunction and associated diseases.


Subject(s)
Areca , Arecoline/pharmacology , Endothelium, Vascular/drug effects , Phytotherapy , Umbilical Arteries/drug effects , Umbilical Veins/drug effects , Vasodilator Agents/pharmacology , Arecoline/administration & dosage , Arecoline/therapeutic use , Blotting, Western , Cell Proliferation/drug effects , Cells, Cultured/drug effects , Cells, Cultured/metabolism , Dose-Response Relationship, Drug , Endothelium, Vascular/metabolism , Female , Flow Cytometry , Humans , Nitric Oxide Synthase Type III/biosynthesis , Nitric Oxide Synthase Type III/drug effects , Pregnancy , Umbilical Arteries/metabolism , Umbilical Veins/metabolism , Vasodilator Agents/administration & dosage , Vasodilator Agents/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL